focus -WSS

focus

author：entertainment 2025-09-06 04:37:04 - browse：26

Medicare and money photo illustration. — Adobe

WASHINGTON — A week after the Food and Drug Administration granted full, traditional approval to a new Alzheimer’s treatment, insurers are finalizing their plans to cover it as well as associated scans and diagnostic tests.

Medicare will cover most patients eligible for Leqembi, a new treatment developed by Eisai and Biogen to help slow the progression of Alzheimer’s disease. The drug, which has modest benefits, has potentially serious side effects for some patients including brain swelling and bleeding.

Medicare told STAT that it would cover brain scans and genetic testing that will help screen for and monitor potential side effects. Medicare already covers one amyloid PET scan per lifetime, but the agency is reconsidering that policy and plans to release a new proposed policy “soon,” an agency spokesperson said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Mayo Clinic plans $5B tech

WSS

Study: New antibiotic targets gonorrhea as well as last existing drug

Takeda, Janssen join wearable maker to measure scratching

10 million people disenrolled from Medicaid over past six months

Just how powerful is the placebo effect?

White House calls on federal agencies to crack down on AI abuses

More doctors should go into startup world

hotspot

focus

hotspot

Virginia high school admissions case could be legal follow

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Despite FDA concern, risk that CAR

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Biotech incubator Curie.Bio graduates its first startup

After affirmative action ruling, medical educators look to 'holistic review'

ReNAgade cuts staff seven months after raising $300 million

Affirmative action in medical school literally saved lives

BIO selects John Crowley as new CEO

focus

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

Diversify hospital leadership teams to protect BIPOC patient health

Diagnostic tests are hitting their mathematical limits

A clever new way to fix Medicaid and graduate medical education

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Free speech concerns arise in wake of journal editor Eisen's firing

entertainment

explore

Wikipedia

leisure time